Selected publications

​

1. Dekkers JF, Whittle JR, Vaillant F, Chen HR, Dawson C, Liu K, Geurts MH, Herold MJ, Clevers H, Lindeman GJ, Visvader JE. Modeling Breast Cancer Using CRISPR-Cas9-Mediated Engineering of Human Breast Organoids. J Natl Cancer Inst. 2020 112(5):540-544. PMID: 31589320
2. Lok SW, Whittle JR, Vaillant F, The CE, Lo LL, Policheni AN, Bergin ART, Desai J, Ftouni S, Gandolfo LC, Liew D, Liu HK, Mann GB, Moodie K, Murugasu A, Pal B, Roberts AW, Rosenthal MA, Shackleton K, Silva MJ, Siow ZR, Smyth GK, Taylor L, Travers A, Yeo B, Yeung M, Zivanovic Bujak A, Dawson SJ, Gray DHD, Visvader JE, Lindeman GJ. A phase 1b dose-escalation and expansion study of the BCL-2 inhibitor venetoclax combined with tamoxifen in ER and BCL-2–positive metastatic breast cancer. Cancer Discovery. 2019 9(3):354-369. PMID 30518523
3. Merino D, Whittle JR, Vaillant F, Serrano A, Gong J-N, Giner G, Maragno A-L, Chanrion M, Schneider E, Pal B, Li X, Dewson G, Gräsel J, Liu K, Lalaoui N, Segal D, Herold MJ, Huang D, Smyth GK, Geneste O, Lessene G, Visvader JE, Lindeman GJ. Synergistic action of the MCL-1 inhibitor S63845 with current therapies in preclinical models of triple negative and HER2-amplified breast cancer. Sci Transl Med. 2017 9(401). pii: eaam7049. PMID: 28768804
4. Nolan E, Savas P, Policheni AN, Darcy PK, Vaillant F, Mintoff C, Mariam Mansour M, Pang J-MB, Fox SB,  kConFab, Perou CM, Visvader JE, Gray DHD, Loi S, Lindeman GJ. Combined immune checkpoint blockade as a therapeutic strategy for BRCA1-mutated breast cancer. Sci Transl Med. 2017 9(393). pii: eaal4922. PMID: 28592566
5. Nolan E, Vaillant F, Branstetter DB, Pal B, Giner G, Whitehead L, Lok SW, Mann GB, kConFab, Rohrbach K, Huang LY, Soriano R, Smyth GK, Dougall WC, Visvader JE*, Lindeman GJ*. RANK ligand as a potential target for breast cancer prevention in BRCA1 mutation carriers. Nature Med. 2016 22(8):933–939. PMID: 27322743 *Equal senior author.
6. Rios AC, Fu NY, Lindeman GJ, Visvader JE. In situ identification of bipotent stem cells in the mammary gland. Nature. 2014 506(7488):322-7. PMID: 24463516.
7. Vaillant F, Merino D, Lee L, Breslin K, Pal B, Ritchie ME, Smyth GK, Christie M, Phillipson LJ, Burns CJ, Mann GB, Visvader JE, Lindeman GJ. Targeting BCL-2 with the BH3 Mimetic ABT-199 in Estrogen Receptor-Positive Breast Cancer. Cancer Cell. 2013 24(1):120-9. PMID: 23845444
8. Asselin-Labat ML, Vaillant F, Sheridan JM, Pal B, Wu D, Simpson ER, Yasuda H, Smyth GK, Martin TJ, Lindeman GJ, Visvader JE. Control of mammary stem cell function by steroid hormone signalling. Nature. 2010 465(7299):798-802. PMID: 20383121.
9. Lim E, Vaillant F, Wu D, Forrest NC, Pal B, Hart AH, Asselin-Labat ML, Gyorki DE, Ward T, Partanen A, Feleppa F, Huschtscha LI, Thorne HJ, Fox SB, Yan M, French JD, Brown MA, Smyth GK, Visvader JE, Lindeman GJ. Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. Nature Medicine. 2009 15(8):907-13. PMID: 19648928.
10. Shackleton M, Vaillant F, Simpson KJ, Stingl J, Smyth GK, Asselin-Labat ML, Wu L, Lindeman GJ, Visvader JE. Generation of a functional mammary gland from a single stem cell. Nature. 2006 439(7072):84-8. PMID: 16397499.

Further publications